nafamostat has been researched along with Liver Failure in 5 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Liver Failure: Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate whether the administration of nafamostat mesilate (NM) reduces the risk of posthepatectomy liver failure (PHLF) in patients undergoing hepatectomy for hepatocellular carcinoma (HCC)." | 8.12 | Effect of postoperative administration of nafamostat mesilate on posthepatectomy liver failure. ( Cho, JY; Han, HS; Jo, Y; Kim, M; Lee, B; Lee, HW; Lee, JS; Yoon, YS, 2022) |
| "To investigate whether the administration of nafamostat mesilate (NM) reduces the risk of posthepatectomy liver failure (PHLF) in patients undergoing hepatectomy for hepatocellular carcinoma (HCC)." | 4.12 | Effect of postoperative administration of nafamostat mesilate on posthepatectomy liver failure. ( Cho, JY; Han, HS; Jo, Y; Kim, M; Lee, B; Lee, HW; Lee, JS; Yoon, YS, 2022) |
| "Nafamostat mesilate was used as an anticoagulant." | 1.29 | [Therapeutic plasmapheresis to treat postoperative hepatic failure clinical course and therapeutic outcome in Japan]. ( Inoue, N; Kodama, M; Tani, T, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, B | 1 |
| Cho, JY | 1 |
| Han, HS | 1 |
| Yoon, YS | 1 |
| Lee, HW | 1 |
| Lee, JS | 1 |
| Kim, M | 1 |
| Jo, Y | 1 |
| Inoue, K | 1 |
| Yoshiba, M | 1 |
| Kodama, M | 1 |
| Tani, T | 1 |
| Inoue, N | 1 |
| Fujioka, H | 1 |
| Eguchi, S | 1 |
| Sugiyama, N | 1 |
| Kawazoe, Y | 1 |
| Kawashita, Y | 1 |
| Kamohara, Y | 1 |
| Azuma, T | 1 |
| Furui, J | 1 |
| Kanematsu, T | 1 |
| Yamashita, Y | 1 |
| Shimada, M | 1 |
| Tsujita, E | 1 |
| Rikimaru, T | 1 |
| Ijima, H | 1 |
| Nakazawa, K | 1 |
| Sakiyama, R | 1 |
| Fukuda, J | 1 |
| Funatsu, K | 1 |
| Sugimachi, K | 1 |
1 review available for nafamostat and Liver Failure
| Article | Year |
|---|---|
[Blood purification for patients with chronic renal failure accompanied by severe liver disease].
Topics: Acute Disease; Anticoagulants; Benzamidines; Carrier State; Cellulose; Chronic Disease; Dialysis Sol | 2004 |
4 other studies available for nafamostat and Liver Failure
| Article | Year |
|---|---|
Effect of postoperative administration of nafamostat mesilate on posthepatectomy liver failure.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Benzamidines; Bilirubin; Carcinoma, Hepatocellula | 2022 |
[Therapeutic plasmapheresis to treat postoperative hepatic failure clinical course and therapeutic outcome in Japan].
Topics: Benzamidines; Guanidines; Humans; Japan; Liver Failure; Plasmapheresis; Postoperative Complications; | 1993 |
Efficacy of Nafamostat Mesilate for improving the performance of a bioartificial liver using porcine hepatocytes.
Topics: Alanine Transaminase; Ammonia; Animals; Benzamidines; Cell Survival; Complement Inactivator Proteins | 1999 |
The efficacy of nafamostat mesilate on the performance of a hybrid-artificial liver using a polyurethane foam/porcine hepatocyte spheroid culture system in human plasma.
Topics: Alanine Transaminase; Ammonia; Animals; Benzamidines; Cell Survival; Female; Guanidines; Humans; Liv | 2001 |